Drug intelligence / Profile preview

CJ-12406

Development stage: Phase 1
Lead developer: CJ CheilJedang
Modality: Small Molecules
Administration: Oral

Overview

CJ-12406 is an investigational small molecule drug developed by CJ CheilJedang for the treatment of gastro-oesophageal reflux disease (GERD). It has undergone phase I clinical trials to evaluate its safety, tolerability, and pharmacokinetics in healthy male subjects. The current global development status is pending, with no evidence of further advancement beyond early clinical studies[1][2][3]. Mechanism of action is not specified in available sources.

Other names: CJ 12406CJ12406CJ-12406

Targets

HTR4 (5-Hydroxytryptamine receptor 4)

Beyond the preview

Go deeper on CJ-12406.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CJ-12406.

Explore the full profile